Track Advagene Biopharma , Ltd.'s total current liabilities ($7.9M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), 6709.TWO shows a total current liabilities of $7.9M. That compares with $6.2M in the prior-year period — up 28.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 6709.TWO's total current liabilities is now $7.9M (was $6.2M) — a 28.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Advagene Biopharma , Ltd. is outperforming or lagging.
Tracking 6709.TWO's total current liabilities over time shows whether Advagene Biopharma , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $7.9M That compares with $6.2M in the prior-year period — up 28.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total current liabilities page, Stockcircle has Advagene Biopharma , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $7.9M) with ownership activity and broader fundamentals.
Advagene Biopharma , Ltd.'s total current liabilities is $7.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.